Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial

Cancer of unknown primary has a dismal prognosis, especially following failure of platinum-based chemotherapy. 10-20% of patients have a high tumor mutational burden (TMB), which predicts response to immunotherapy in many cancer types. In this prospective, non-randomized, open-label, multicenter Pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Pouyiourou, Maria, Kraft, Bianca N., Wohlfromm, Timothy, Stahl, Michael, Kubuschok, Boris, Löffler, Harald, Hacker, Ulrich T., Hübner, Gerdt, Weiss, Lena, Bitzer, Michael, Ernst, Thomas, Schütt, Philipp, Hielscher, Thomas, Delorme, Stefan, Kirchner, Martina, Kazdal, Daniel, Ball, Markus, Kluck, Klaus, Stenzinger, Albrecht, Bochtler, Tilmann, Krämer, Alwin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598029/
https://www.ncbi.nlm.nih.gov/pubmed/37875494
http://dx.doi.org/10.1038/s41467-023-42400-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598029/
https://www.ncbi.nlm.nih.gov/pubmed/37875494
http://dx.doi.org/10.1038/s41467-023-42400-5

Ejemplares similares